Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Names 9 Candidates for Independent Safety Monitoring Panel for Pharma Products
September 3, 2020
- AMED Confirms 1st COVID-19 Case at HQ
September 3, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- AMED to Fund 7 More Company-Led COVID-19 Vaccine Projects Including Takeda, Daiichi Sankyo
September 2, 2020
- Japan Rolls Out Full-Fledged Sakigake System, Designations 2 Times a Year with Tougher Revocation Rules
September 1, 2020
- AMED to Focus on 5 Initiatives Including Strengthening Cooperation with Govt: New Chief
September 1, 2020
- Healthcare Spend Reaches Record 43.6 Trillion Yen in FY2019: MHLW
September 1, 2020
- MHLW Panel Roughly OKs Report on Stable API Supply Measures
August 31, 2020
- With Abe Hitting Exit, Industry Eyes Riveted on FY2021 Off-Year Re-Pricing Plan
August 31, 2020
- Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
- MHLW Set to Address API, Coronavirus Vaccine Issues in FY2021 Budget
August 28, 2020
- Japan’s 1st Topical Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Now in Line for September Approval
August 28, 2020
- MHLW Panels Agree to Prioritize Flu Vaccinations for Elderly, and Then HCPs
August 27, 2020
- MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
- MHLW Vows Thorough Post-Approval Safety Follow-Up on COVID-19 Vaccines: Official
August 27, 2020
- MHLW Likely to Secure Largest Volume of Flu Vaccines since Quadrivalent Switch: Kato
August 26, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Up for MHLW Panel Review on Sept.4
August 25, 2020
- MHLW OKs Label Expansions for Keytruda, Imfinzi, Kadcyla
August 24, 2020
- Japan to Look at H1N1 Flu Rules to Consider Indemnity for COVID-19 Vaccine Makers
August 24, 2020
- MHLW Panel to Ask Osaka Univ. Hospital to Quickly Report on Scientific Validity of Paper: Fabricated Data Scandal
August 24, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…